Capital Investment in Growth Areas and Production Capacity Expansion
First written in FY2016. 13 of 41 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026.
35 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The Company decided to build a new plant at its Toyohashi facility to further expand its existing business areas. The new plant is scheduled to produce electrical-release tape used in smartphones and other products, optical clear adhesive sheets used in foldable products incorporating OLEDs, which are attracting attention in next-generation high-end devices, and tapes for securing components.」
The Company decided to build a new plant at its Toyohashi facility for electrical-release tape, transparent adhesive sheets for OLED foldable products and other products. Separately, it also disclosed an investment of ¥39.0 billion, the largest in its history. - FY2026-H1Semiannual capital investment results updatedAnnual report
「Cash used in investing activities totaled ¥56,348 million, compared with ¥67,328 million in the same period of the previous year. This was primarily the result of a decrease of ¥51,088 million from expenditures for the acquisition of property, plant and equipment and intangible assets, ¥3,550 million from changes in time deposits, and ¥2,353 million from expenditures for the acquisition of investment securities.」
During the interim period, investing activities included expenditures of ¥51,088 million for the acquisition of property, plant and equipment and intangible assets. - FY2025AdvancedAnnual report
「Capital expenditures by the Group during the fiscal year totaled ¥92,976 million.」
Full-year capital expenditures totaled ¥92,976 million and were allocated to expanding production capacity for circuit materials, information functional materials and contract manufacturing of nucleic acid drugs, among other areas. - FY2025-H1Semiannual capital investment results updatedAnnual report
「This was primarily the result of a decrease of ¥56,787 million from expenditures for the acquisition of property, plant and equipment and intangible assets, ¥3,877 million from changes in time deposits, and ¥6,256 million from expenditures for the acquisition of shares in affiliates.」
During the interim consolidated accounting period, investing activities included expenditures of ¥56,787 million for the acquisition of tangible and intangible assets and ¥6,256 million for the acquisition of shares in affiliates. - FY2024AdvancedAnnual report
「Capital expenditures by the Group during the fiscal year totaled ¥83,445 million. In Industrial Tapes, ¥17,427 million was spent on measures including expanding adhesive tape production capacity and replacing aging buildings and equipment. In Optoelectronics, ¥30,240 million was spent on measures including expanding production capacity for optical films for the growth areas of automotive displays and VR, and improving the productivity of high-precision substrates in circuit materials. In Human Life, ¥30,674 million was spent on measures including establishing a production system to commercialize contract manufacturing of nucleic acid drugs.」
Full-year capital expenditures totaled ¥83,445 million and were allocated to growth areas including automotive and VR applications, circuit materials and contract manufacturing of nucleic acid drugs. - FY2024-Q3Updated third-quarter capital investment resultsAnnual report
「This was primarily the result of a decrease of ¥51,114 million from expenditures for the acquisition of property, plant and equipment and intangible assets and ¥2,078 million from changes in time deposits, partly offset by an increase of ¥1,871 million from proceeds from the sale of shares in subsidiaries resulting in a change in the scope of consolidation.」
Expenditures for the acquisition of property, plant and equipment and intangible assets during the cumulative third quarter totaled ¥51,114 million. - FY2024-Q2Semiannual capital investment results updatedAnnual report
「Cash used in investing activities totaled ¥30,386 million, compared with ¥129,397 million in the same period of the previous year. This was primarily the result of a decrease of ¥32,394 million from expenditures for the acquisition of property, plant and equipment and intangible assets, partly offset by an increase of ¥1,871 million from proceeds from the sale of shares in subsidiaries resulting in a change in the scope of consolidation.」
During the cumulative second quarter of FY2024, investing activities included expenditures of ¥32,394 million for the acquisition of property, plant and equipment and intangible assets, with ¥1,871 million received from the sale of shares in subsidiaries. - FY2024-Q1Updated first-quarter capital investment resultsAnnual report
「This was primarily the result of a decrease of ¥16,785 million from expenditures for the acquisition of property, plant and equipment and intangible assets, partly offset by an increase of ¥1,871 million from proceeds from the sale of shares in subsidiaries resulting in a change in the scope of consolidation.」
During the first quarter of FY2024, investing activities included expenditures of ¥16,785 million for the acquisition of property, plant and equipment and intangible assets. - FY2024-Q1AdvancedAnnual report
「Products for VR displays began production on a new production line.」
For optical films for VR applications, a new production line began operations, and the production capacity expansion entered the implementation phase. - FY2023Updated full-year capital expenditure results and new construction plansAnnual report
「Capital expenditures by the Group during the fiscal year totaled ¥50,789 million. In Industrial Tapes, ¥14,763 million was spent on measures including expanding adhesive tape production capacity. In Optoelectronics, ¥24,372 million was spent on measures including expanding production capacity for optical films for VR applications and establishing a CIS production system in printed circuits. In Human Life, ¥6,197 million was spent on measures including establishing a production system for nucleic acid drugs.」
Full-year capital expenditures totaled ¥50,789 million and were allocated to growth areas including optical films for VR applications, CIS and nucleic acid drugs. - FY2023-Q3Updated third-quarter capital expenditure and acquisition investment resultsAnnual report
「Cash used in investing activities totaled ¥142,529 million, compared with ¥41,406 million in the same period of the previous year. This was primarily the result of a decrease of ¥50,653 million from expenditures for the acquisition of property, plant and equipment and intangible assets and ¥95,411 million from expenditures for the acquisition of shares in subsidiaries resulting in a change in the scope of consolidation, partly offset by an increase of ¥2,566 million from proceeds from the sale of investment securities.」
During the cumulative third quarter, investing activities included expenditures of ¥50,653 million for the acquisition of tangible and intangible assets and ¥95,411 million for the acquisition of shares in subsidiaries. - FY2023-Q2Updated first-half capital expenditure and acquisition investment resultsAnnual report
「This was primarily the result of a decrease of ¥34,295 million from expenditures for the acquisition of property, plant and equipment and intangible assets and ¥95,411 million from expenditures for the acquisition of shares in subsidiaries resulting in a change in the scope of consolidation.」
The Company disclosed expenditures of ¥34,295 million for capital expenditures during the cumulative second quarter and ¥95,411 million for the acquisition of shares in subsidiaries. - FY2023-Q1Updated first-quarter capital expenditure and acquisition investment resultsAnnual report
「This was primarily the result of a decrease of ¥15,812 million from expenditures for the acquisition of property, plant and equipment and intangible assets and ¥95,411 million from expenditures for the acquisition of shares in subsidiaries resulting in a change in the scope of consolidation.」
During the first quarter, investing activities included expenditures of ¥15,812 million for the acquisition of tangible and intangible assets and ¥95,411 million for the acquisition of shares in subsidiaries, including Mondi and Bend. - FY2022Full-year capital expenditure updateAnnual report
「Capital expenditures by the Group during the fiscal year totaled ¥56,496 million. In Industrial Tapes, ¥14,278 million was spent on measures including expanding adhesive tape production capacity. In Optoelectronics, ¥25,212 million was spent on measures including improving optical film productivity and establishing a production system for high-precision substrates in printed circuits. In Life Sciences, ¥4,458 million was spent on measures including establishing a production system for nucleic acid drugs.」
Full-year capital expenditures totaled ¥56,496 million and were allocated to optical films, high-precision substrates and nucleic acid drug production systems, among other areas. - FY2022-Q3Updated third-quarter capital investment resultsAnnual report
「This was primarily the result of a decrease of ¥43,274 million from expenditures for the acquisition of property, plant and equipment and intangible assets.」
Expenditures for the acquisition of property, plant and equipment and intangible assets during the cumulative third quarter totaled ¥43,274 million. - FY2022-Q2Semiannual capital investment results updatedAnnual report
「This was primarily the result of a decrease of ¥29,457 million from expenditures for the acquisition of property, plant and equipment and intangible assets.」
Expenditures for the acquisition of property, plant and equipment and intangible assets during the cumulative second quarter totaled ¥29,457 million. - FY2022-Q1Updated first-quarter capital investment resultsAnnual report
「Cash used in investing activities totaled ¥11,965 million, compared with ¥16,057 million in the same period of the previous year. This was primarily the result of a decrease of ¥12,120 million from expenditures for the acquisition of property, plant and equipment and intangible assets.」
During the first quarter of FY2022, investing activities included expenditures of ¥12,120 million for the acquisition of property, plant and equipment and intangible assets. - FY2021Full-year capital expenditure updateAnnual report
「Capital expenditures by the Group (the Company and its affiliates) during the fiscal year totaled ¥50,597 million. In Industrial Tapes, ¥12,660 million was spent on measures including expanding adhesive tape production capacity. In Optoelectronics, ¥29,697 million was spent on measures including improving optical film productivity and establishing a production system for high-precision substrates in printed circuits. In Life Sciences, ¥1,358 million was spent on measures including establishing a production system for nucleic acid drugs.」
Full-year capital expenditures totaled ¥50,597 million and were allocated to areas including Optoelectronics' high-precision substrate production system and Life Sciences' nucleic acid drug production system. - FY2021-Q3Updated third-quarter capital investment resultsAnnual report
「This was primarily the result of a decrease of ¥44,972 million from expenditures for the acquisition of property, plant and equipment and intangible assets.」
During the cumulative third quarter, investing activities included expenditures of ¥44,972 million for the acquisition of property, plant and equipment and intangible assets. - FY2021-Q2Semiannual capital investment results updatedAnnual report
「Cash used in investing activities totaled ¥30,392 million, compared with ¥36,345 million in the same period of the previous year. This was primarily the result of a decrease of ¥30,107 million from expenditures for the acquisition of property, plant and equipment and intangible assets.」
During the cumulative second quarter, investing activities included expenditures of ¥30,107 million for the acquisition of property, plant and equipment and intangible assets. - FY2021-Q1Updated first-quarter capital investment resultsAnnual report
「This was primarily the result of a decrease of ¥15,581 million from expenditures for the acquisition of property, plant and equipment and intangible assets, and ¥879 million from expenditures for the acquisition of shares in affiliates.」
During the first quarter, investing activities included expenditures of ¥15,581 million for the acquisition of tangible and intangible assets and ¥879 million for the acquisition of shares in affiliates. - FY2020AdvancedAnnual report
「During the consolidated fiscal year, the group (the company and its affiliated companies) made total capital investments of ¥58,930 million. Industrial Tape invested ¥15,261 million to improve adhesive tape productivity and contribute to environmental initiatives in manufacturing. Optoelectronics invested ¥30,257 million, including to improve optical film productivity and establish a production system for high-precision substrates for printed circuits.」
Full-year capital expenditures totaled ¥58,930 million and were allocated to adhesive tapes, optical films and high-precision substrates, among other areas. - FY2020-Q3Updated third-quarter capital investment resultsAnnual report
「This was primarily the result of a decrease due to ¥48,245 million in expenditures for the acquisition of property, plant and equipment and intangible assets and ¥2,418 million in changes in time deposits.」
Investing activities during the first nine months included ¥48,245 million in expenditures for the acquisition of property, plant and equipment and intangible assets. - FY2020-Q2Semiannual capital investment results updatedAnnual report
「This was primarily the result of a decrease due to ¥34,387 million in expenditures for the acquisition of property, plant and equipment and intangible assets and ¥1,492 million in changes in time deposits.」
Expenditures for the acquisition of property, plant and equipment and intangible assets during the first six months totaled ¥34,387 million. - FY2020-Q1Updated first-quarter capital investment resultsAnnual report
「This was primarily the result of a decrease due to ¥17,264 million in expenditures for the acquisition of property, plant and equipment and intangible assets and ¥1,385 million in changes in time deposits.」
Investing activities during the first quarter included ¥17,264 million in expenditures for the acquisition of property, plant and equipment and intangible assets. - FY2019AdvancedAnnual report
「During the consolidated fiscal year, the group (the company and its affiliated companies) made total capital investments of ¥64,353 million. Industrial Tape invested ¥21,972 million, including to expand adhesive tape production capacity at the Toyohashi site. Optoelectronics invested ¥34,474 million, including to install production equipment in China for new polarizing plates.」
Full-year capital investment increased to ¥64,353 million, allocated to adhesive tape production in Toyohashi and production equipment in China for new polarizing plates, among other areas. - FY2019-Q3Updated third-quarter capital investment resultsAnnual report
「This was primarily the result of a decrease due to ¥45,688 million in expenditures for the acquisition of property, plant and equipment and intangible assets, ¥6,350 million in changes in time deposits, and an increase due to ¥2,634 million in proceeds from the sale of shares in subsidiaries involving a change in the scope of consolidation.」
Expenditures for the acquisition of property, plant and equipment and intangible assets during the first nine months totaled ¥45,688 million. The company updated its investment results, including capital investment in growth areas. - FY2019-Q2Semiannual capital investment results updatedAnnual report
「This was primarily the result of a decrease due to ¥30,887 million in expenditures for the acquisition of property, plant and equipment and intangible assets, ¥3,345 million in changes in time deposits, and an increase due to ¥2,634 million in proceeds from the sale of shares in subsidiaries involving a change in the scope of consolidation.」
Investing activities during the first six months included ¥30,887 million in expenditures for the acquisition of tangible and intangible assets. The company also reported ¥2,634 million in proceeds from the sale of shares in subsidiaries. - FY2019-Q1Updated first-quarter capital investment resultsAnnual report
「Investing activities resulted in a decrease in funds of ¥12,730 million, compared with a decrease of ¥10,747 million in the same quarter of the previous year. This was primarily due to a ¥15,583 million decrease from expenditures for the acquisition of property, plant and equipment and intangible assets, partly offset by ¥2,634 million in proceeds from the sale of shares in subsidiaries involving a change in the scope of consolidation.」
Investing activities during the quarter included ¥15,583 million in expenditures for the acquisition of property, plant and equipment and intangible assets. - FY2018AdvancedAnnual report
「During the consolidated fiscal year, the group (the company and its affiliated companies) made total capital investments of ¥47,193 million. Industrial Tape invested ¥18,356 million, including to expand production capacity for fluorine porous materials at the Kanto site. Optoelectronics invested ¥16,994 million, including to construct a plant in China for new polarizing plates. Life Sciences invested ¥5,476 million, mainly to expand production capacity in North America.」
The company made total capital investments of ¥47,193 million in growth areas, allocating funds to fluorine porous materials, new polarizing plates and capacity expansion in North American life sciences. - FY2018-Q3Updated third-quarter capital investment resultsAnnual report
「This was primarily the result of a decrease due to ¥35,744 million in expenditures for the acquisition of property, plant and equipment and intangible assets and ¥3,223 million in changes in time deposits.」
Expenditures for the acquisition of tangible and intangible assets during the first nine months totaled ¥35,744 million. - FY2018-Q2AdvancedAnnual report
「The company added manufacturing equipment for nucleic acid pharmaceutical active ingredients, increasing existing production capacity to more than double, and began operations in August.」
In contract manufacturing of nucleic acid pharmaceuticals in North America, the capital investment to increase manufacturing capacity to more than double was completed, and operations began in August. - FY2018-Q1AdvancedAnnual report
「In the North American contract manufacturing business for nucleic acid therapeutics, the company made an investment to more than double production capacity in order to further strengthen its market advantage as the industry leader.」
In contract manufacturing of nucleic acid pharmaceuticals in North America, the company invested to more than double production capacity. Capital investment and capacity expansion in growth areas are taking concrete shape. - FY2017AdvancedAnnual report
「During the consolidated fiscal year, the group (the company and its affiliated companies) made total capital investments of ¥36,538 million. Industrial Tape invested ¥15,310 million, including to expand production capacity for automotive tapes in North America. Optoelectronics invested ¥13,160 million, including in back-end equipment for information functional materials in East Asia and environmental-related investments at the Kameyama site. Life Sciences invested ¥1,778 million, mainly to expand production capacity in North America.」
The company made ¥36,538 million in capital investments for the full year, allocating funds to growth areas including automotive tapes, information functional materials and life sciences production capacity in North America. - FY2017-Q3AdvancedAnnual report
「This was primarily the result of a decrease due to ¥34,827 million in expenditures for the acquisition of property, plant and equipment and intangible assets and ¥4,796 million in expenditures for the acquisition of shares in subsidiaries involving a change in the scope of consolidation.」
Investing activities during the first nine months included expenditures of ¥34,827 million for the acquisition of tangible and intangible assets and ¥4,796 million for the acquisition of shares in subsidiaries. In the life sciences business, the company also expanded facilities in addition to pursuing M&A. - FY2017-Q2Updated capital investment resultsAnnual report
「This was primarily the result of a decrease due to ¥22,716 million in expenditures for the acquisition of property, plant and equipment and intangible assets and ¥4,796 million in expenditures for the acquisition of shares in subsidiaries involving a change in the scope of consolidation.」
Investing activities during the first six months included ¥22,716 million in expenditures for the acquisition of tangible and intangible assets. A further ¥4,796 million in expenditures for the acquisition of shares in subsidiaries was also recorded. - FY2017-Q1AdvancedAnnual report
「The company decided to establish integrated production in Shenzhen, China, from the front-end process for a new optical film by around fiscal 2018, and began capital investment in June.」
The company decided to establish integrated production in Shenzhen, China, from the front-end process for a new optical film by around fiscal 2018, and began capital investment in June. - FY2016First statedAnnual report
「During the consolidated fiscal year, the group (the company and its affiliated companies) made total capital investments of ¥60,420 million, primarily in growth areas such as information functional materials.」
Capital investment for the fiscal year totaled ¥60,420 million, focused mainly on growth areas such as information functional materials and on expanding production capacity across the businesses.